These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24523730)

  • 1. HMGB1 Is Involved in the Protective Effect of the PPAR α Agonist Fenofibrate against Cardiac Hypertrophy.
    Jia Z; Xue R; Liu G; Li L; Yang J; Pi G; Ma S; Kan Q
    PPAR Res; 2014; 2014():541394. PubMed ID: 24523730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure.
    Funayama A; Shishido T; Netsu S; Narumi T; Kadowaki S; Takahashi H; Miyamoto T; Watanabe T; Woo CH; Abe J; Kuwahara K; Nakao K; Takeishi Y; Kubota I
    Cardiovasc Res; 2013 Sep; 99(4):657-64. PubMed ID: 23708738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Reduction in ADAM17 Expression Is Involved in the Protective Effect of the PPAR-
    Zeng SY; Lu HQ; Yan QJ; Zou J
    PPAR Res; 2018; 2018():7916953. PubMed ID: 30105051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor γ agonist troglitazone inhibits high mobility group box 1 expression in endothelial cells via suppressing transcriptional activity of nuclear factor κB and activator protein 1.
    Gao M; Hu Z; Zheng Y; Zeng Y; Shen X; Zhong D; He F
    Shock; 2011 Sep; 36(3):228-34. PubMed ID: 21617575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
    Irukayama-Tomobe Y; Miyauchi T; Sakai S; Kasuya Y; Ogata T; Takanashi M; Iemitsu M; Sudo T; Goto K; Yamaguchi I
    Circulation; 2004 Feb; 109(7):904-10. PubMed ID: 14967736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.
    Irukayama-Tomobe Y; Miyauchi T; Kasuya Y; Sakai S; Goto K; Yamaguchi I
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S358-61. PubMed ID: 15838320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure.
    Zhang L; Liu M; Jiang H; Yu Y; Yu P; Tong R; Wu J; Zhang S; Yao K; Zou Y; Ge J
    J Cell Mol Med; 2016 Mar; 20(3):459-70. PubMed ID: 26647902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
    Rose M; Balakumar P; Singh M
    Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
    Liang F; Wang F; Zhang S; Gardner DG
    Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Peroxisome Proliferator Activated Receptor α (PPAR α) for the Prevention of Mitochondrial Impairment and Hypertrophy in Cardiomyocytes.
    Kar D; Bandyopadhyay A
    Cell Physiol Biochem; 2018; 49(1):245-259. PubMed ID: 30138942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.
    Xu J; Storer PD; Chavis JA; Racke MK; Drew PD
    J Neurosci Res; 2005 Aug; 81(3):403-11. PubMed ID: 15968640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
    Zou J; Le K; Xu S; Chen J; Liu Z; Chao X; Geng B; Luo J; Zeng S; Ye J; Liu P
    Mol Cell Endocrinol; 2013 May; 370(1-2):103-12. PubMed ID: 23518069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
    Duhaney TA; Cui L; Rude MK; Lebrasseur NK; Ngoy S; De Silva DS; Siwik DA; Liao R; Sam F
    Hypertension; 2007 May; 49(5):1084-94. PubMed ID: 17353509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
    Ye P; Fang H; Zhou X; He YL; Liu YX
    Chin Med Sci J; 2004 Dec; 19(4):243-7. PubMed ID: 15669179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin.
    Jen HL; Yin WH; Chen JW; Lin SJ
    J Atheroscler Thromb; 2017 May; 24(5):508-517. PubMed ID: 27629528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.
    Li R; Zheng W; Pi R; Gao J; Zhang H; Wang P; Le K; Liu P
    FEBS Lett; 2007 Jul; 581(17):3311-6. PubMed ID: 17597616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
    Purushothaman S; Sathik MM; Nair RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):254-62. PubMed ID: 21654328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
    Diep QN; Benkirane K; Amiri F; Cohn JS; Endemann D; Schiffrin EL
    J Mol Cell Cardiol; 2004 Feb; 36(2):295-304. PubMed ID: 14871557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of peroxisome proliferator-activated receptor γ by rosiglitazone inhibits lipopolysaccharide-induced release of high mobility group box 1.
    Hwang JS; Kang ES; Ham SA; Yoo T; Lee H; Paek KS; Park C; Kim JH; Lim DS; Seo HG
    Mediators Inflamm; 2012; 2012():352807. PubMed ID: 23316104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate unexpectedly induces cardiac hypertrophy in mice lacking MuRF1.
    Parry TL; Desai G; Schisler JC; Li L; Quintana MT; Stanley N; Lockyer P; Patterson C; Willis MS
    Cardiovasc Pathol; 2016; 25(2):127-140. PubMed ID: 26764147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.